EANS-Adhoc

Marinomed Biotech AG resumes offer period of the IPO - Seite 2

The transaction meets the requirements of a qualified public offer in accordance
with the terms and conditions of the convertible bonds issued in 2017 that are
traded on the Third Market of the Vienna Stock Exchange. Following successful
completion of the Offering, convertible bondholders are expected to be entitled
from 1 February 2019 to convert their bonds into new shares of Marinomed Biotech
AG in accordance with the terms and conditions of the convertible bond (start of
conversion period, which, according to the terms and conditions of the
convertible bonds, lasts two weeks, hence until and including 14 February 2019).
The Conversion Price I (as defined in the terms and conditions of the
convertible bonds) to be adjusted on the basis of the final Offer Price is
expected to be determined and announced on 29 January 2019.

Marinomed Biotech AG reserves the right to premature termination, interruption
or suspension of the Offering, extension or shortening of the Offer Period.

About Marinomed Biotech AG
Marinomed Biotech AG is a Vienna based biopharmaceutical company focusing on the
development of innovative products derived from patent protected technology
platforms to treat respiratory and ophthalmic conditions. The Carragelose®
platform comprises innovative patent protected products targeting viral
infections of the respiratory tract. Carragelose® is used in nasal sprays,
throat sprays and lozenges, which are sold in more than 30 countries around the
world in collaboration with international partners. The Marinosolv® technology
platform increases the efficacy of hardly soluble compounds for the treatment of
sensitive tissues such as the eyes and nose. Further information is available at
www.marinomed.com.

Disclaimer

This announcement does not constitute an offer to purchase securities or
solicitation of an offer to purchase securities in the United States of America,
Germany, Austria or other jurisdictions. The shares (the "Shares") of Marinomed
Biotech AG (the "Company") may only be sold or offered for sale after prior
registration in the United States of America upon or without prior registration
by virtue of an exemption from the registration requirement under the provisions
of the US Securities Act of 1933, as amended. The Company does not intend to
fully or partially register any offer of Shares in the United States or to make
any public offering of Shares in the United States.

A public offering of securities of the Company in Austria is made solely by, and
on the basis of, a prospectus (including the supplements thereto) for securities
prepared and published in accordance with the provisions of the Capital Markets
Act (Kapitalmarktgesetz), which was approved and published on 16 November 2018.
An investment decision regarding publicly offered securities of the Company
should only be made on the basis of such a prospectus. Any purchase orders
relating to securities of the Company received prior to the resumption of the
public offering will be rejected. The prospectus as well as the supplements
thereto are available free of charge at Marinomed Biotech AG, Veterinärplatz 1,
A-1210 Vienna, or on the website of Marinomed Biotech AG (https://
www.marinomed.com/offering).









Further inquiry note:
Eva Prieschl-Grassauer, PhD
Chief Scientific Officer, Marinomed
Veterinärplatz 1, 1210 Vienna, Austria
Tel.: [phone]
E-mail: [e-mail]
http://www.marinomed.com

Roland Mayrl
Managing Partner, Metrum Communications
Prinz-Eugen-Straße 80/16, 1040 Vienna, Austria
Tel.: [phone]
E-mail: [e-mail]
http://www.metrum.at


end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Marinomed Biotech AG
Veterinärplatz 1
A-1210 Wien
phone: [phone]
FAX: [phone]
mail: [e-mail]
WWW: www.marinomed.com
ISIN: AT0000A1WD52, ATMARINOMED6
indexes:
stockmarkets: Wien
language: English